Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

13.11
+0.27002.10%
Volume:3.11M
Turnover:40.52M
Market Cap:1.55B
PE:-3.44
High:13.34
Open:12.93
Low:12.66
Close:12.84
52wk High:28.25
52wk Low:5.90
Shares:118.13M
Float Shares:112.00M
Volume Ratio:0.94
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8100
EPS(LYR):-3.8100
ROE:-53.48%
ROA:-27.11%
PB:2.31
PE(LYR):-3.44

Loading ...

Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?

Simply Wall St.
·
Mar 10

Intellia Therapeutics Awards 16,500 RSU Inducement Grants Under 2024 Plan

Reuters
·
Mar 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Intellia Therapeutics Raised to Buy From Hold by Jones Trading

Dow Jones
·
Mar 04

Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 04

Stock Track | Intellia Therapeutics Soars 5.77% in Pre-Market After Analyst Upgrade to Buy

Stock Track
·
Mar 04

Intellia Therapeutics Inc : Jonestrading Raises to Buy From Hold

THOMSON REUTERS
·
Mar 04

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

Stock Track | Intellia Therapeutics Plummets 7.34% Intraday on Dilution Fears from $400 Million Stock Sale Plan

Stock Track
·
Mar 03

Intellia Presents Three-Year Lonvo-z Data Showing 96% HAE Attack Reduction

Reuters
·
Mar 03

RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 03

Intellia Therapeutics price target lowered to $48 from $54 at Canaccord

TIPRANKS
·
Mar 03

Intellia Therapeutics, Inc. : Wells Fargo Raises Target Price to $15 From $12

THOMSON REUTERS
·
Mar 03

Stock Track | Intellia Therapeutics Plunges 6.02% in Pre-market on $400 Million Stock Sale Plan

Stock Track
·
Mar 03

Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement

Stock Track
·
Mar 03

Intellia Therapeutics Inc - Entered Sale Agreement With Jefferies for up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Mar 03

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 03

Intellia Therapeutics price target raised to $27 from $26 at Chardan

TIPRANKS
·
Mar 03

William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform

MT Newswires Live
·
Mar 03

Intellia Therapeutics upgraded at William Blair after clinical hold lifted

TIPRANKS
·
Mar 03